129 related articles for article (PubMed ID: 22773127)
1. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT.
Khaled Y; Al-Hazzouri A; Mizrachi A; Reynolds R; Reddy V; Solh M
Bone Marrow Transplant; 2013 Feb; 48(2):310-1. PubMed ID: 22773127
[No Abstract] [Full Text] [Related]
2. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
3. New developments in conditioning regimens before auto-SCT in multiple myeloma.
Moreau P; Attal M; Harousseau JL
Bone Marrow Transplant; 2011 Jul; 46(7):911-5. PubMed ID: 21358678
[TBL] [Abstract][Full Text] [Related]
4. Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!
Mohty M
Leukemia; 2009 Oct; 23(10):1689-90. PubMed ID: 19826430
[No Abstract] [Full Text] [Related]
5. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Imataki O; Aoyama T; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
[TBL] [Abstract][Full Text] [Related]
7. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
8. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis.
Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203
[No Abstract] [Full Text] [Related]
9. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
10. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
Moreau P; Milpied N; Mahé B; Juge-Morineau N; Rapp MJ; Bataille R; Harousseau JL
Bone Marrow Transplant; 1999 May; 23(10):1003-6. PubMed ID: 10373065
[TBL] [Abstract][Full Text] [Related]
11. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.
Knudsen LM; Rasmussen T; Jensen L; Johnsen HE
Med Oncol; 1999 Dec; 16(4):245-54. PubMed ID: 10618687
[TBL] [Abstract][Full Text] [Related]
12. Impaired PBPC collection in patients with myeloma after high-dose melphalan.
Jansen J; Thompson J; Dugan M; Wiemann M; Hanks S; Greenspan A; Akard L
Cytotherapy; 2004; 6(5):498-504. PubMed ID: 15512916
[TBL] [Abstract][Full Text] [Related]
13. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
14. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Borad MJ; Swift R; Berenson JR
Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
[No Abstract] [Full Text] [Related]
16. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
17. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
Lazarus HM; Phillips GL; Herzig RH; Hurd DD; Wolff SN; Herzig GP
J Clin Oncol; 2008 May; 26(14):2240-3. PubMed ID: 18467711
[No Abstract] [Full Text] [Related]
18. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
[No Abstract] [Full Text] [Related]
19. Outpatient high-dose melphalan in multiple myeloma patients.
Kassar M; Medoff E; Seropian S; Cooper DL
Transfusion; 2007 Jan; 47(1):115-9. PubMed ID: 17207239
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]